Dr. Marie Wikström Lindholm profile page

Dr. Marie Wikström Lindholm is the CSO of Silence Therapeutics, leading a skilled team focusing on fine-tuning design of GalNAc-conjugated siRNA and exploring extra-hepatocyte siRNA targeting. Marie has a PhD in medical chemistry from Uppsala University, Sweden and was an associate professor in experimental cardiovascular medicine at Lund University before moving to industry. In 2007, Marie joined the Danish biotechnology company Santaris Pharma, working on LNA oligonucleotide research. Santaris Pharma was acquired by Roche and Marie was appointed expert scientist in discovery technology and head of targeted delivery of oligonucleotide conjugates. Marie has authored >60 patents and scientific publications, many in the fields of antisense drug design, safety and function.